Providing investors with the
tools to make informed decisions.
Providing investors with the
tools to make informed decisions.
 Tracking 1050 U.S. listed China Stocks and Counting...
 Tracking 1535 U.S. Stocks and Counting...

 China Health Industries (OTC BB:CHHE)

Monday, December 28, 2009

China Health was formed on July 20, 2007  for the purpose of seeking and consummating a merger or acquisition with a business entity.

On August 20, 2007, the sole shareholder of China Health entered into a Share Purchase Agreement with the owners of Humankind.

On December 31, 2008, China Health closed a reverse merger with Universal Fog, Inc, a U.S. public traded shell company.

Harbin Humankind Biology Technology Co., is in the business of the manufacture and sale of health products, “green” (or organic) food and the detection of disease susceptibility or pre-disposition through genetic studies. Harbin Huimeijia Medicine Company was incorporated on October 14, 2008. Huimeijia completed its GMP certification on July 23, 2009 and will be producing and selling our medical drugs.

Financial Summary:

Fiscal Yr. Ends June Full Year 2009 Full Year 2008 Period Change
GAAP Revenue $10.98 million $763.60 thousand 1337.93%
GAAP EPS $0.05 $0.00 n/a
Tax Rate 34.36% n/a n/a 
Fully Diluted Shares 62,234,737 61,203,088 1.69%

Source: See SEC Filing (For the period ended June 2009) 

Fiscal Qtr. Ends September 1st Quarter 2010 1st Quarter 2009 Period Change
GAAP Revenue $10.25 million $286.21 thousand 3481.29%
GAAP EPS $0.06 $0.00 n/a
Tax Rate 25.31% n/a n/a
Fully Diluted Shares 62,234,737 62,234,732 0.00%

We anticipate our total revenues in 2010 versus 2009 to increase by 101% or approximately $11.04 million with growth in all categories of our product sales. Our gross profit margin in 2010 is expected to be approximately 55.45% due to raw material cost inflation. Operating expenses will increase due to higher percentage of R&D investment as well as expanding our own distribution channels. We estimate our overall 2009 net profit margins to be approximately 22.64%.However, there is no assurance that these predictions will be reached.

Source: See SEC Filing (For the quarterly period ended September 30, 2009)